Following the completion of the Kenvue separation, Johnson & Johnson (NYSE:JNJ) revised its financials and 2023 guidance. The Consumer Health business financial results will now be presented as discontinued operations, encompassing a gain of approximately $20 billion in Q3/23. The company disclosed a total sales figure of $42.41 billion for the first half of its fiscal year, with adjusted earnings per share amounting to $4.97.
JNJ’s updated guidance reveals expectations of adjusted operational sales growth of 6.7%, excluding the Consumer Health business. This contrasts with the earlier projection of 6.5% growth that included the Consumer Health business.
Post-Kenvue separation, operational sales are projected to range from $83.6 billion to $84.4 billion, marking a change from the previous estimate of $99.3 billion to $100.3 billion. Adjusted earnings per share have been revised to $10.05, down from the previous $10.75.